•  
  •  
  •  
  •  

2025-11-29 21:43:57

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Cantabil Retail India Ltd opens 3 new shops in November 2025
  • Advait Energy Transitions Ltd receives order from Malaysia
  • SRM Contractors Ltd receives ET Infra Leadership Award 2025
  • Ceinsys Tech Ltd receives additional order from MRSAC
  • Apeejay Surrendra Park Hotels Ltd inks MoU for 42 room hotel in Mathura

Keywords Selected:  BioconBiologics

Stock Report

  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • U.S. FDA Completes Inspection at Biocon Biologics' Facility at Biocon Campus, Bengaluru, India
  • Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™
  • Biocon Biologics receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars
  • Biocon Biologics expands Insulin Access in Malaysia
  • Biocon Biologics receives Health Canada approval for Yesafili™
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
  • Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • Biocon Biologics and Civica, Inc. collaborate to expand Insulin Aspart access in the United States
  • Biocon Biologics Launches Yesintekâ„¢ Biosimilar to Stelara® in the United States
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • EMA's CHMP recommends approval of Biocon Biologics' YESINTEK®, biosimilar to J&J's Stelara®
  • Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence
  • U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
  • Biocon Biologics Refinances USD 1.1 Billion Long Term Debt through USD Bonds and New Syndicated Facility
  • Biocon Biologics announces New Dermatology Data to be presented at EADV Congress 2024
  • Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara®, in Europe, UK, Canada, and Japan

Latest Post

  • Cantabil Retail India Ltd opens 3 new shops in November 2025
  • Advait Energy Transitions Ltd receives order from Malaysia
  • SRM Contractors Ltd receives ET Infra Leadership Award 2025
  • Ceinsys Tech Ltd receives additional order from MRSAC
  • Apeejay Surrendra Park Hotels Ltd inks MoU for 42 room hotel in Mathura


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024